{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:10:36Z","timestamp":1791429036831,"version":"4.3.3"},"reference-count":15,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.xcrm.2025.101972","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T11:07:07Z","timestamp":1739876827000},"page":"101972","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["How close are we to a cAMP- and cGMP-theory-based pharmacological therapy for fragile X syndrome?"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6411-1517","authenticated-orcid":false,"given":"Barbara","family":"Bardoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Gwizdek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Maurin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2025.101972_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41583-021-00432-0","article-title":"The molecular biology of FMRP: new insights into fragile X syndrome","volume":"22","author":"Richter","year":"2021","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.xcrm.2025.101972_bib2","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.neubiorev.2008.06.005","article-title":"The cyclic AMP phenotype of fragile X and autism","volume":"32","author":"Kelley","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.xcrm.2025.101972_bib3","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1038\/s41380-020-00997-9","article-title":"Role of phosphodiesterases in the pathophysiology of neurodevelopmental disorders","volume":"26","author":"Delhaye","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.101972_bib4","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1523\/JNEUROSCI.1356-12.2015","article-title":"PDE-4 inhibition rescues aberrant synaptic plasticity in Drosophila and mouse models of fragile X syndrome","volume":"35","author":"Choi","year":"2015","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.xcrm.2025.101972_bib5","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1093\/cercor\/bhy192","article-title":"Involvement of Phosphodiesterase 2A Activity in the Pathophysiology of Fragile X Syndrome","volume":"29","author":"Maurin","year":"2019","journal-title":"Cereb Cortex"},{"key":"10.1016\/j.xcrm.2025.101972_bib6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41398-022-01885-2","article-title":"Phosphodiesterase 2A inhibition corrects the aberrant behavioral traits observed in genetic and environmental preclinical models of Autism Spectrum Disorder","volume":"12","author":"Schiavi","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.xcrm.2025.101972_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2023.106393","article-title":"Defects in AMPAR trafficking and microglia activation underlie socio-cognitive deficits associated to decreased expression of phosphodiesterase 2 a","volume":"191","author":"Delhaye","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.xcrm.2025.101972_bib8","article-title":"Haploinsufficiency of PDE2A causes in mice increased exploratory behavior associated with upregulation of neural nitric oxide synthase in the striatum","volume":"205","author":"de Oliveira do R\u00eago","year":"2025","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.xcrm.2025.101972_bib9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.xcrm.2025.101972_bib10","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13229-024-00626-0","article-title":"Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndrome","volume":"15","author":"Norris","year":"2024","journal-title":"Mol. Autism."},{"key":"10.1016\/j.xcrm.2025.101972_bib11","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/02698811241273814","article-title":"Safety, tolerability and pharmacokinetics of the phosphodiesterase 2 inhibitor BI 474121: An overview of phase I randomized trials in healthy volunteers","volume":"38","author":"Schaible","year":"2024","journal-title":"J.\u00a0Psychopharmacol."},{"key":"10.1016\/j.xcrm.2025.101972_bib12","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1111\/bcp.16137","article-title":"Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies","volume":"90","author":"van Kraaij","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.xcrm.2025.101972_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108414","article-title":"Inhibition of PDE2 and PDE4 synergistically improves memory consolidation processes","volume":"184","author":"Paes","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.xcrm.2025.101972_bib14","article-title":"Longevity, enhanced memory, and altered density of dendritic spines in hippocampal CA3 and dentate gyrus after hemizygous deletion of Pde2a in mice","author":"Baumg\u00e4rtel","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.xcrm.2025.101972_bib15","first-page":"253","article-title":"Mice with a naturally occurring DISC1 mutation display a broad spectrum of behaviors associated to psychiatric disorders","volume":"8","author":"G\u00f3mez-Sintes","year":"2014","journal-title":"Front. Behav. Neurosci."}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500045X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266637912500045X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T20:36:41Z","timestamp":1772483801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266637912500045X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S266637912500045X"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101972","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How close are we to a cAMP- and cGMP-theory-based pharmacological therapy for fragile X syndrome?","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2025.101972","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101972"}}